Economic estimates have indicated that 2.25 billion coffees are consumed every day – this is a significant number. Researchers at the Department of Ophthalmology, Hubei… Read More »Anyone for a coffee – instant coffee may increase the risk of AMD, and reducing instant coffee intake can prevent dry AMD.
An independent study, funded by the Swedish government, has reported that intravitreal injections of anti-VEGF treatments were associated with a 2.9% risk for stroke among… Read More »Swedish clinical study reports a 3% increased risk of stroke within 90 days of anti-VEGF treatments.
A Phase 3 randomised clinical trial has recruited of >400 patients in a seven-month period, driven by clinical and patient interest, according to the trial’s… Read More »Phase 3 trial of vorolanib intravitreal insert, using a tyrosine kinase inhibitor (TKI), will be evaluating for wet age-related macular degeneration (wet AMD).
Clinical researchers at the Department of Ophthalmology and the Vision Centre of Excellence, Akron Children’s Hospital, Ohio, have reported a molecular diagnostic rate of 41.5%… Read More »Clinical research on patients with infantile nystagmus syndrome (INS), across several inherited ocular diseases, may provide significant support for counselling and on-going clinical trials.
Clinical researchers at the Sorbonne Université, INSERM, CNRS, Institut de la Vision and the Centre Hospitalier National d’Ophtalmologie des Quinze-Vingts, Paris, have reported PCARE-associated retinopathy… Read More »Natural history of PCARE-associated retinopathy highlights genetics, clinical characteristics and time-to-event curves for development of atrophy.
A consortium of clinical researchers and trial experts have launched a new updated statement published by 39 researchers*, led by Professor Sally Hopewell, based in… Read More »New “CONSORT 2025 statement” has announced an expanded checklist to optimally conduct high-quality research on randomised trials.
Clinical researchers at the Sorbonne Université, INSERM, Institut de la Vision, Paris, have reported multiple pathogenic variants in the RP1L1 gene, associated with autosomal dominant,… Read More »Clinical analysis of phenotypic and genotypic characteristics on retinitis pigmentosa-1-like-1 (RP1L1) show associated retinopathy.
EMA (European Medicines Authority) officials have launched a new clinical trial map aimed to provide access to the public for “patients and healthcare professionals with… Read More »EMA launches a new clinical trial map aimed at increasing access to clinical research studies in the European Union (EU).
Researchers based at the Singapore National Eye Centre, and the Ophthalmology and Visual Sciences, Duke-NUS Graduate Medical School, Singapore, have published a report showing clear… Read More »Clinical distinctions between EYS- and USH2A-associated Retinitis Pigmentosa (RP) provides important implications for diagnosis, counselling and clinical practice.
Evidence presented in the journal The Lancet (Lancet 2025; 405: 648–57) have reported substantial benefits with improved visual acuity and functional vision following a treatment… Read More »Evidence of rescue of vision with gene supplementation for young patients diagnosed with variants in AIPL1-LCA4.
